Journal of Diagnostics

Published by: Asian Medical Journals
Online ISSN: 2409-322X
Print ISSN: 2413-8371
Quick Submission    Login/Submit/Track

Recent Articles

The Outcome and Hepatic Function of an Extended Category II Treatment in a HIV-Seronegative Suspected Extensively Drug-Resistant TB Patient

Pages: 1-6
Find References

Finding References


The Outcome and Hepatic Function of an Extended Category II Treatment in a HIV-Seronegative Suspected Extensively Drug-Resistant TB Patient

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

DOI: 10.18488/journal.98.2020.71.1.6

Ato Kwamena Tetteh , Edward Agyarko , Joseph Otchere , Langbong Bimi , Irene Ayi

Export to    BibTeX   |   EndNote   |   RIS

[1]          World Health Organization (WHO), Global tuberculosis report: WHO/ HTM/TB/2016.13. Geneva, Switzerland: World Health Organization, 2016.

[2]          C. A. Bonilla, A. Crossa, H. O. Jave, C. D. Mitnick, R. B. Jamanca, C. Herrera, L. Asencios, A. Mendoza, J. Bayona, and M. Zignol, "Management of extensively drug-resistant tuberculosis in Peru: Cure is possible," PLoS One, vol. 3, 2008.

[3]          World Health Organization (WHO), "Management of MDR-TB: A field guide: A companion document to guidelines for programmatic management of drug-resistant tuberculosis: Integrated management of adolescent and adult illness," (IMAI). WHO/HTM/TB/2008, 2008.

[4]          N. S. Shah, A. Wright, G.-H. Bai, L. Barrera, F. Boulahbal, N. Martín-Casabona, F. Drobniewski, C. Gilpin, M. Havelková, and R. Lepe, "Worldwide emergence of extensively drug-resistant tuberculosis," Emerging Infectious Diseases, vol. 13, pp. 380-387, 2007.

[5]          World Health Organization (WHO), "Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response," Report No. WHO/HTM/TB/2010.3. Geneva: The Organization2010.

[6]          A. Matteelli, G. B. Migliori, D. Cirillo, R. Centis, E. Girard, and M. Raviglione, "Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: Epidemiology and control," Expert Review of Anti-Infective Therapy, vol. 5, pp. 857-871, 2007.

[7]          G. B. Migliori, G. Besozzi, E. Girardi, K. Kliiman, C. Lange, O. Toungoussova, G. Ferrara, D. Cirillo, A. Gori, and A. Matteelli, "Clinical and operational value of the extensively drug-resistant tuberculosis definition," European Respiratory Journal, vol. 30, pp. 623-626, 2007. Available at: https://doi.org/10.1183/09031936.00077307.

[8]          H. S. Cox, C. Sibilia, S. Feuerriegel, S. Kalon, J. Polonsky, A. K. Khamraev, S. Rüsch-Gerdes, C. Mills, and S. Niemann, "Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis," New England Journal of Medicine, vol. 359, pp. 2398-2400, 2008. Available at: https://doi.org/10.1056/nejmc0805644.

[9]          A. D. Calver, M. Murray, O. J. Strauss, E. M. Streicher, M. Hanekom, T. Liversage, M. Masibi, P. D. Van Helden, R. M. Warren, and T. C. Victor, "Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa," Emerging Infectious Diseases, vol. 16, p. 264, 2010. Available at: https://doi.org/10.3201/eid1602.090968.

[10]        N. R. Gandhi, A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland, "Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa," The Lancet, vol. 368, pp. 1575-1580, 2006. Available at: https://doi.org/10.1016/s0140-6736(06)69573-1.

[11]        C. D. Mitnick, S. S. Shin, K. J. Seung, M. L. Rich, S. S. Atwood, J. J. Furin, G. M. Fitzmaurice, V. F. A. Alcantara, S. C. Appleton, J. N. Bayona, C. A. Bonilla, S. K. Chalco, M. F. Choi, H. S. Franke, D. Fraser, R. M. Guerra, D. Hurtado, K. Jazayeri, K. Joseph, L. Llaro, J. S. Mestanza, M. Mukherjee, E. Muñoz, E. Palacios, A. Sanchez, Sloutsky, and M. C. Becerra, "Comprehensive treatment of extensively drug-resistant tuberculosis," The New England Journal of Medicine, vol. 359, pp. 563–74, 2008.

[12]        S. D. Lawn, P. Mwaba, M. Bates, A. Piatek, H. Alexander, B. J. Marais, L. E. Cuevas, T. D. McHugh, L. Zijenah, and N. Kapata, "Advances in tuberculosis diagnostics: The Xpert MTB/RIF assay and future prospects for a point-of-care test," The Lancet Infectious Diseases, vol. 13, pp. 349-361, 2013. Available at: https://doi.org/10.1016/s1473-3099(13)70008-2.

[13]        World Health Organization (WHO), Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO, 2017.

[14]        M. Cheesbrough, District laboratory practice in tropical countries: Cambridge University Press, 2006.

[15]        R. M. Green and S. Flamm, "AGA technical review on the evaluation of liver chemistry tests," Gastroenterology, vol. 123, pp. 1367-1384, 2002. Available at: https://doi.org/10.1053/gast.2002.36061.

[16]        C. Benichou, "Criteria of drug-induced liver disorders. Report of an international consensus meeting," Journal of Hepatology, vol. 11, pp. 272-276, 1990. Available at: https://doi.org/10.1016/0168-8278(90)90124-a.

[17]        D. R. Dufour, J. A. Lott, F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff, "Diagnosis and monitoring of hepatic injury: I. Performance characteristics of laboratory tests," Clinical Chemistry, vol. 46, pp. 2027–2049, 2000a.

[18]        D. R. Dufour, J. A. Lott, F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff, "Diagnosis and monitoring of hepatic injury: II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring," Clinical Chemistry, vol. 46, pp. 2050–2068, 2000b.

[19]        D. Larrey, "Epidemiology and individual susceptibility to adverse drug reactions affecting the liver," Seminars in Liver Disease, vol. 22, pp. 145–156, 2002. Available at: https://doi.org/10.1055/s-2002-30101.

[20]        G. M. Williams and M. J. Iatropoulos, "Alteration of liver cell function and proliferation: Differentiation between adaptation and toxicity," Toxicologic Pathology, vol. 30, pp. 41-53, 2002. Available at: https://doi.org/10.1080/01926230252824699.

[21]        A. K. Tetteh, E. Agyarko, J. Otchere, L. Bimi, and I. Ayi, "An evaluation of treatment outcomes in a cohort of clients on the DOTS strategy, 2012-2016," Tuberculosis Research and Treatment, p. 7, 2018.

[22]        World Health Organization (WHO), Improving the diagnosis and treatment of smear negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: Recommendation for HIV-prevalent and resource-constrained setting. Geneva: WHO, 2007.

[23]        World Health Organization (WHO), Xpert MTB/RIF implementation manual: Technical and operational ‘how to’ practical considerations. Geneva: WHO, 2014.

[24]        World Health Organization (WHO), "Guidelines for the pragmatic management of drug-resistant tuberculosis," WHO/HTM/TB/2008.402, 2008.

Ato Kwamena Tetteh , Edward Agyarko , Joseph Otchere , Langbong Bimi , Irene Ayi (2020). The Outcome and Hepatic Function of an Extended Category II Treatment in a HIV-Seronegative Suspected Extensively Drug-Resistant TB Patient. Journal of Diagnostics, 7(1): 1-6. DOI: 10.18488/journal.98.2020.71.1.6
A 25 year old HIV- seronegative client was diagnosed with pulmonary tuberculosis and placed on Category I (CAT I) treatment. After two months, acid fast bacilli (AFB) persisted in sputum. Rifampicin (Rif) resistance was detected with the GeneXpert MTB-Rif Assay® (Xpert; Cepheid, Sunnyvale, CA, USA), leading to a change in treatment to CAT II after completing CAT I in the third month. Continuous detection of Rif resistant species and persisting ‘Scanty’ results (1-9 AFB found in 100 microscopic fields) from sputum smear microscopy (SSM) after one (1) year was suggestive of treatment failure to CAT II [possible extensively drug-resistant (XDR) species]. Category II treatment was continued for the next eight months as we anticipated the arrival of XDR medicines. Before commencement of XDR medication, SSM and GeneXpert were repeated. The SSM result was negative (no AFB seen), while Rif resistance persisted. The controversy was eventually clarified with the Bactec Mycobacteria Growth Indicator Tube (MGIT) liquid culture, which indicated no growth for M. tuberculosis. Since the rapid molecular GeneXpert will persistently detect Rif resistance even after months of treatment, we support the use of MGIT to confirm when treatment should be halted. This case study also showed tolerance to prolonged treatment with CAT I and II drugs and confirms evidence in existing literature.
Contribution/ Originality
The outcome of this case study contributes to existing literature on laboratory and clinical diagnosis, and the management of pulmonary tuberculosis. It further reinforces the need to equip district level laboratories adequately to expedite diagnosis.